SALT LAKE CITY, April 1, 2021 /PRNewswire/ — Cūrza Global, LLC (Cūrza) announced today that The Institute for Therapeutic Innovation (ITI) at the University of Florida has been awarded a $75M contract from the Defense Threat Reduction Agency (DTRA) in partnership with Cūrza. This program is aimed at the development of Cūrza’s CZ-02 platform of antibiotics for the treatment of drug-resistant bacterial infections. The CZ-02 platform represents a novel class of antibacterial agents with a unique mode of action.
Antibiotic-resistant superbugs represent a global health crisis. “The COVID-19 virus pandemic has also heightened awareness of the deficiencies in our current arsenal of antibacterial drugs”, commented John W. Kozarich, CEO of Cūrza. “We are pleased to expand our collaboration with ITI to advance our platform, not only for treatments of community and hospital-associated pathogens, but also to now include those with significant biothreat potential. If successful, these unique molecules will represent the first new class of antibiotics discovered in the last 60 years with activity against these pathogens.”
The contract provides Cūrza with funding to advance novel CZ-02s into clinical development. Chad Testa, Ph.D., Vice President of Research at Cūrza will serve as Principal Investigator (PI) for Cūrza. Henry Heine, Ph.D. of ITI will be the PI for the full contract.
For more information, please contact:
John Kozarich, CEO
Cūrza Global, LLC
SOURCE Curza Global, LLC